Publications
Abdelhady, R., Mohammed, O.A., Doghish, A.S., Hamad, R.S., Mustafa Ahmed Abdel‐Reheim, Alamri, M.S., Muffarah Hamid Alharthi, Jaber Alfaifi, Adam, Abdullah Hassan Alhalafi, Mohammed, N.A., Adamu Imam Isa, Sameh Abdel‐Ghany, Attia, M.A., Elmorsy, E.A., Tohada M. AL‐Noshokaty, Yousra Nomier, El‐Dakroury, W.A. and Saber, S. (2024). Linagliptin, a DPP‐4 inhibitor, activates AMPK/FOXO3a and suppresses NFκB to mitigate the debilitating effects of diethylnitrosamine exposure in rat liver: Novel mechanistic insights. The FASEB Journal, 38(4). doi:.
Mohammed, O.A., Abdel-Reheim, M.A., Saleh, L.A., Alamri, M.M.S., Alfaifi, J., Adam, M.I., Farrag, A.A., AlQahtani, A.A.J., BinAfif, W.F., Hashish, A.A. and Abdel-Ghany, S., 2023. Alvespimycin exhibits potential anti-TGF-β signaling in the setting of a proteasome activator in rats with bleomycin-induced pulmonary fibrosis: a promising novel approach. Pharmaceuticals, 16(8), p.1123.
Mohammed, O.A., Abdel-Reheim, M.A., Alamri, M.M.S., Alfaifi, J., Adam, M.I., Saleh, L.A., Farrag, A.A., Yahia, A.I.O., Abdel-Ghany, S., AlQahtani, A.A.J. and Bahashwan, E., 2023. STA9090 as a potential therapeutic agent for liver fibrosis by modulating the HSP90/TβRII/proteasome interplay: novel insights from in vitro and in vivo investigations. Pharmaceuticals, 16(8), p.1080. Saber, S., Alamri, M.M.S., Alfaifi, J., Saleh, L.A., Abdel-Ghany, S., Aboregela, A.M., Farrag, A.A., Almaeen, A.H., Adam, M.I., AlQahtani, A.A.J. and E
